Genmab AS - Company & Market Research Reports

Genmab is a leading biotechnology company that focuses on developing innovative antibody products. Arzerra is the company’s first marketed antibody and is approved to treat chronic lymphocytic leukemia (CLL) patients in all major markets. Another product, Darzalex, has been approved in the United States for the treatment of patients with multiple myeloma. Genmab was founded in Copenhagen, Denmark in 1999 and employs around 200 people.


Global Cancer Monoclonal Antibodies Market & Pipeline Insight - Product Thumbnail Image

Global Cancer Monoclonal Antibodies Market & Pipeline Insight

  • Drug Pipelines
  • 1400 Pages
From
Bispecific Antibodies: Clinical Trial Tracker - Product Thumbnail Image

Bispecific Antibodies: Clinical Trial Tracker

  • Clinical Trials
From
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016 - Product Thumbnail Image

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2016

  • Report
  • 722 Pages
From
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016 - Product Thumbnail Image

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H1 2016

  • Report
  • 713 Pages
From
Squamous Cell Carcinoma - Pipeline Review, H1 2014 - Product Thumbnail Image

Squamous Cell Carcinoma - Pipeline Review, H1 2014

  • Report
  • 153 Pages
From
Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments - Product Thumbnail Image

Multiple Myeloma Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Velcade, Revlimid and Emerging Supplementary Treatments

  • Report
  • 117 Pages
From
Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments - Product Thumbnail Image

Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments

  • Report
  • 119 Pages
From
Rheumatoid Arthritis Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Rheumatoid Arthritis Therapeutics - Global Strategic Business Report

  • Report
  • 824 Pages
From
Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020 - Product Thumbnail Image

Global Cancer Immunotoxins Market & Clinical Pipeline Insight 2020

  • Drug Pipelines
  • 240 Pages
From
T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals - Product Thumbnail Image

T-Cell Redirecting Bispecific Antibodies 2016: A Competitive Landscape Analysis of Stakeholders, Technologies, Pipelines and Deals

  • Report
  • 230 Pages
From
Report package: T-Cell Immunotherapy by Bispecific Antibodies and CAR & TCR Engineered T-cells - Product Thumbnail Image

Report package: T-Cell Immunotherapy by Bispecific Antibodies and CAR & TCR Engineered T-cells

  • Report
  • 618 Pages
From
Bladder and Ureter Cancer Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

  • Report
  • 150 Pages
From
Thyroid Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Thyroid Cancer - Pipeline Review, H1 2018

  • Report
  • 567 Pages
From
Diabetic Macular Edema - Pipeline Review, H1 2018 - Product Thumbnail Image

Diabetic Macular Edema - Pipeline Review, H1 2018

  • Report
  • 209 Pages
From
Diabetic Macular Edema - Pipeline Review, H2 2017 - Product Thumbnail Image

Diabetic Macular Edema - Pipeline Review, H2 2017

  • Report
  • 193 Pages
From
 What's Trending in Monoclonal Antibodies (Market by Structure [Chimeric, Humanized], by Target [EGFR, TNF, HER2, CD20,PD-1, Other] and by Disease [Autoimmune, Oncology, Neurological, Other]) - Product Thumbnail Image

What's Trending in Monoclonal Antibodies (Market by Structure [Chimeric, Humanized], by Target [EGFR, TNF, HER2, CD20,PD-1, Other] and by Disease [Autoimmune, Oncology, Neurological, Other])

  • Report
  • 203 Pages
From
Global Monoclonal Antibodies Pipeline Insight 2015 - Product Thumbnail Image

Global Monoclonal Antibodies Pipeline Insight 2015

  • Drug Pipelines
  • 1600 Pages
From
Global Cancer Monoclonal Antibodies Market 2017-2021 - Product Thumbnail Image

Global Cancer Monoclonal Antibodies Market 2017-2021

  • Report
  • 115 Pages
From
Global Monoclonal Antibodies Market 2016-2020 - Product Thumbnail Image

Global Monoclonal Antibodies Market 2016-2020

  • Report
  • 160 Pages
From
Global Cancer Monoclonal Antibodies Market - Growth, Trends, Forecasts 2017 - 2022 - Product Thumbnail Image

Global Cancer Monoclonal Antibodies Market - Growth, Trends, Forecasts 2017 - 2022

  • Report
  • 205 Pages
From
Loading Indicator
adroll